Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.
Scott R. Solomon, MD, medical director, Northside Hospital Blood and Marrow Transplant Matched Unrelated Donor Program and Northside Hospital Stem Cell Processing Laboratory, physician, Northside Hospital Leukemia Program, discusses the effects of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma (B-NHL) who were previously treated with CD19-directed therapies.
During the 2021 Transplantation and Cellular Therapy Meetings, findings from a post-hoc analysis of the phase 1 TRANSCEND NHL 001 trial were presented virtually. The results showed that 11 out of 12 patients with relapsed/refractory B-NHL who had previously received anti-CD19 therapy responded to liso-cel treatment, Solomon says. Moreover, 2 patients had complete responses, 3 had partial responses, and 1 had stable disease.
Five patients experienced a duration of response to liso-cel of 9 months or longer, and 4 patients had ongoing responses at the time of the data cut-off, Solomon says. As such, these data suggest that prior exposure to CD19-directed therapy does not negatively affect the efficacy of liso-cel in this patient population, concludes Solomon.